Drug Profile

Herpes zoster vaccine - MAXVAX Biotechnology

Alternative Names: Recombinant Herpes Zoster Vaccine - MAXVAX Biotechnology; Shingles vaccine - MAXVAX Biotechnology

Latest Information Update: 24 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Dec 2025 MAXVAX Biotechnology plans a phase-III trial for Herpes zoster (Prevention) in China (IM), (NCT07293065)
23 Oct 2024 MAXVAX Biotechnology plans a phase III trial for Herpes zoster (Prevention, In adults, In the elderly) in China (IM, Injection), in November 2024 (NCT06654700)
13 Jul 2024 Phase-III clinical trials in Herpes zoster (Prevention) in China (IM) (NCT06447779)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com